Posttransplant TKI initiation, dosing, continuous use, and 85% use in year 1
| Variable . | All (N = 81), n (%) . | CR1 MAC (n = 26), n (%) . | CR1 NMAC (n = 43), n (%) . | P . | CR2+ (n = 12), n (%) . | Median time to posttransplant TKI start (range), d . | Median duration of continuous treatment with first posttransplant TKI (range), d . | Mean TKI dosing in year 1 posttransplant . |
|---|---|---|---|---|---|---|---|---|
| First posttransplant TKI | ||||||||
| Imatinib | 19 (23.5) | 9 (34.6) | 9 (20.9) | 1 (8.3) | 48.5 (36-143) | 183 (1-2698) | 393.2 mg | |
| Dasatinib | 35 (43.2) | 11 (42.3) | 20 (46.5) | 4 (33.3) | 53.5 (32-389) | 75 (1-1664) | 79.6 mg | |
| Nilotinib | 13 (16) | 4 (15.34) | 8 (18.6) | 1 (8.3) | 66 (36-117) | 368 (23-1607) | 300.8 mg | |
| Bosutinib | 1 (1.2) | 0 | 1 (2.3) | 75 | 1654 | 500 mg | ||
| Ponatinib | 6 (7.4) | 0 | 2 (4.7) | 4 (33.3) | 61 (31-119) | 153 (9-916) | 26.5 mg | |
| None | 7 (8.6) | 2 (7.7) | 3 (7.0) | 2 (16.7) | ||||
| Received TKI on 85% of nonrelapse evaluable days 31-395 | 36 (44.4) | 9 (34.6) | 22 (51.1) | .22 | 5 (41.7) | Dosing is daily, except nilotinib, which is twice daily |
| Variable . | All (N = 81), n (%) . | CR1 MAC (n = 26), n (%) . | CR1 NMAC (n = 43), n (%) . | P . | CR2+ (n = 12), n (%) . | Median time to posttransplant TKI start (range), d . | Median duration of continuous treatment with first posttransplant TKI (range), d . | Mean TKI dosing in year 1 posttransplant . |
|---|---|---|---|---|---|---|---|---|
| First posttransplant TKI | ||||||||
| Imatinib | 19 (23.5) | 9 (34.6) | 9 (20.9) | 1 (8.3) | 48.5 (36-143) | 183 (1-2698) | 393.2 mg | |
| Dasatinib | 35 (43.2) | 11 (42.3) | 20 (46.5) | 4 (33.3) | 53.5 (32-389) | 75 (1-1664) | 79.6 mg | |
| Nilotinib | 13 (16) | 4 (15.34) | 8 (18.6) | 1 (8.3) | 66 (36-117) | 368 (23-1607) | 300.8 mg | |
| Bosutinib | 1 (1.2) | 0 | 1 (2.3) | 75 | 1654 | 500 mg | ||
| Ponatinib | 6 (7.4) | 0 | 2 (4.7) | 4 (33.3) | 61 (31-119) | 153 (9-916) | 26.5 mg | |
| None | 7 (8.6) | 2 (7.7) | 3 (7.0) | 2 (16.7) | ||||
| Received TKI on 85% of nonrelapse evaluable days 31-395 | 36 (44.4) | 9 (34.6) | 22 (51.1) | .22 | 5 (41.7) | Dosing is daily, except nilotinib, which is twice daily |